GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Blum Holdings Inc (OTCPK:BLMH) » Definitions » Beneish M-Score

BLMH (Blum Holdings) Beneish M-Score : -0.42 (As of Dec. 12, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Blum Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.42 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Blum Holdings's Beneish M-Score or its related term are showing as below:

BLMH' s Beneish M-Score Range Over the Past 10 Years
Min: -8.46   Med: -2.76   Max: 20.55
Current: -0.42

During the past 13 years, the highest Beneish M-Score of Blum Holdings was 20.55. The lowest was -8.46. And the median was -2.76.


Blum Holdings Beneish M-Score Historical Data

The historical data trend for Blum Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blum Holdings Beneish M-Score Chart

Blum Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.44 -4.37 -3.88 4.15 -7.57

Blum Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.42 -4.13 -0.71 -0.74 -0.42

Competitive Comparison of Blum Holdings's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Blum Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blum Holdings's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Blum Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Blum Holdings's Beneish M-Score falls into.



Blum Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Blum Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.3657+0.528 * 0.7445+0.404 * 1.2011+0.892 * 0.2858+0.115 * 15.9604
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.7145+4.679 * -0.033792-0.327 * 0.8419
=-0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Mar23) TTM:
Total Receivables was $0.88 Mil.
Revenue was 4.364 + 3.795 + 1.549 + 2.267 = $11.98 Mil.
Gross Profit was 2.448 + 1.592 + 0.526 + 1.181 = $5.75 Mil.
Total Current Assets was $3.55 Mil.
Total Assets was $38.68 Mil.
Property, Plant and Equipment(Net PPE) was $10.34 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.31 Mil.
Selling, General, & Admin. Expense(SGA) was $21.23 Mil.
Total Current Liabilities was $51.87 Mil.
Long-Term Debt & Capital Lease Obligation was $8.50 Mil.
Net Income was -3.344 + 23.843 + -3.362 + -3.248 = $13.89 Mil.
Non Operating Income was -0.69 + 12.883 + 1.769 + -0.103 = $13.86 Mil.
Cash Flow from Operations was -0.458 + 0 + 0.76 + 1.035 = $1.34 Mil.
Total Receivables was $1.29 Mil.
Revenue was 8.729 + 7.644 + 9.721 + 15.801 = $41.90 Mil.
Gross Profit was 4.184 + 2.739 + -0.042 + 8.087 = $14.97 Mil.
Total Current Assets was $5.53 Mil.
Total Assets was $39.47 Mil.
Property, Plant and Equipment(Net PPE) was $12.88 Mil.
Depreciation, Depletion and Amortization(DDA) was $10.86 Mil.
Selling, General, & Admin. Expense(SGA) was $43.33 Mil.
Total Current Liabilities was $38.61 Mil.
Long-Term Debt & Capital Lease Obligation was $34.55 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.875 / 11.975) / (1.294 / 41.895)
=0.073069 / 0.030887
=2.3657

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(14.968 / 41.895) / (5.747 / 11.975)
=0.357274 / 0.479916
=0.7445

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3.549 + 10.337) / 38.678) / (1 - (5.526 + 12.878) / 39.466)
=0.640985 / 0.533675
=1.2011

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=11.975 / 41.895
=0.2858

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(10.857 / (10.857 + 12.878)) / (0.305 / (0.305 + 10.337))
=0.457426 / 0.02866
=15.9604

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(21.234 / 11.975) / (43.329 / 41.895)
=1.773194 / 1.034228
=1.7145

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((8.5 + 51.868) / 38.678) / ((34.554 + 38.614) / 39.466)
=1.560784 / 1.85395
=0.8419

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(13.889 - 13.859 - 1.337) / 38.678
=-0.033792

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Blum Holdings has a M-score of -0.42 signals that the company is likely to be a manipulator.


Blum Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Blum Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Blum Holdings Business Description

Traded in Other Exchanges
N/A
Address
3242 S. Halladay Street, Suite 202, Santa Ana, CA, USA, 92705
Blum Holdings Inc is a cannabis company with operations in retail, production, distribution, and cultivation, with an emphasis on providing the highest quality of medical and adult-use cannabis products. It distributes its own branded products as well as third-party products to its retail dispensaries in California under the Korova brand. The company has two reportable segments; Cannabis Retail which generates key revenue and includes cannabis-focused retail, both physical stores and non-store front delivery, and the Cannabis Distribution segment which includes cannabis distribution operations.
Executives
Patty Chan officer: CHIEF FINANCIAL OFFICER 11516 DOWNEY AVE, DOWNEY CA 90241
Oren Schauble officer: President 3242 S HALLADAY ST., SUITE 202, SANTA ANA CA 92705
Dallas Imbimbo director 1800 NEWPORT CIRCLE, SANTA ANA CA 92705
Eric Baum director 866 BERKSHIRE DRIVE, WESTBURY NY 11590
Tiffany N. Davis director 11852 MANHATTAN CT., RANCHO CUCAMONGA CA 91730
Michael Nahass director 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Derek Peterson director, officer: President and CEO 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Alan David Gladstone other: Former Director of Issuer P.O BOX 9699, NEWPORT BEACH CA 92658
Uri Kenig officer: Chief Operating Officer 2040 MAIN ST., SUITE 225, IRVINE CA 92614
Ira E. Ritter director C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
Nicholas Kovacevich director 2618 SAN MIGUEL DRIVE, #480, NEWPORT BEACH CA 92660
Knuettel Ii Francis director 205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Jeffrey Robert Batliner officer: Chief Financial Officer 2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Megan Jimenez officer: Chief Financial Officer 2040 MAIN ST., SUITE 225, IRVINE CA 92614
Matthew Morgan director, officer: Chief Executive Officer 2040 MAIN STREET, SUITE 225, IRVINE CA 92614